Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.

Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.